Treatment of central precocious puberty

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 16, Issue 1, 2009, Pages 31-36

  Kaplowitz, Paul B ^a,b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Adult height; Gonadotropin releasing hormone; Histrelin implant; Precocious puberty

Indexed keywords

BUSERELIN; FOLLITROPIN; GONADORELIN DERIVATIVE; GOSERELIN; HISTRELIN; LEUPRORELIN; LUTEINIZING HORMONE; OXANDROLONE; TRIPTORELIN;

BODY HEIGHT; BREAST DEVELOPMENT; CLINICAL FEATURE; COST BENEFIT ANALYSIS; DELAYED PUBERTY; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DOSE RESPONSE; EMOTIONAL STRESS; HORMONAL REGULATION; HUMAN; LABORATORY TEST; PRECOCIOUS PUBERTY; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TURNER SYNDROME;

ADULT; BODY HEIGHT; BREAST; CHILD; FEMALE; HUMANS; LUTEINIZING HORMONE; LUTEOLYTIC AGENTS; MALE; PUBERTY, PRECOCIOUS; SEX CHARACTERISTICS; TRIPTORELIN;

EID: 58849144343     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e328320a650     Document Type: Review

References (22)

1. Kaplowitz PB. Pubertal development in girls: secular trends. Curr Opin Obstet Gynecol 2006; 18:487-491.
2. Anderson SE, Must A. Interpreting the continued decline in the average age at menarche: results from two nationally representative surveys of U.S. girls studied 10 years apart. J Pediatr 2005; 147:753-760.
3. Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatrics Research in Office Settings network. Pediatrics 1997; 99:505-512.
4. Wu T, Mendola P, Buck GM. Ethnic differences in the presence of secondary sex characteristics and menarche among US girls: the third National Health and Nutrition Examination Survey, 1988-1994. Pediatrics 2002; 110:752-757.
5. Kaplowitz PB, Oberfield SE, the Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Pediatrics 1999; 104:936-941.
6. Chalumeau M, Chemaitilly W, Trivin C, et al. Central precocious puberty in girls: an evidence-based diagnosis tree to predict central nervous system abnormalities. Pediatrics 2002; 109:61-67.
7. Palmert MR, Malin HV, Boepple PA. Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients. J Clin Endocrinol Metab 1999; 84:415-423.
8. Fontoura M, Brauner R, Prevot C, Rappoport R. Precocious puberty in girls: early diagnosis of a slowly progressing variant. Arch Dis Child 1989; 64:1170-1176.
9. Neely EK, Wilson DM, Lee PA, et al. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr 1995; 127:47-52.
10. Resende EA, Lara BH, Reis JD, et al. Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children. J Clin Endocrinol Metab 2007; 92:1424-1429. This study systematically looked at basal and stimulated LH values in 107 normal boys and girls and concluded that there was more overlap for girls than for boys, but that the ICMA method provided better separation than the IFMA method for pubertal vs. prepubertal children.
11. Pasquino AM, Pucarelli I, Accardo F, et al. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008; 93:190-195. An excellent retrospective study that examined several variables related to adult height attainment, and unlike in most CPP studies, there was an untreated control group.
12. Carel J-C, Lahlou N, Jaramillo O, et al. Treatment of central precocious puberty by subcutaneous injections of Leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 2002; 87:4111-4116.
13. Badura A, Wilson DM, Bachrach LK, et al. Sequential comparison of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab 2006; 91:1862-1867.
14. Foster CM. Editorial: does lupron dosage make a difference in outcome when treating children with precocious puberty? J Clin Endocrinol Metab 2006; 91:1667-1668.
15. Martinez-Aguayo A, Hernandez MI, Beas F, et al. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation. J Pediatr Endocrinol Metab 2006; 19:963-970.
16. Isaac H, Patel L, Meyer S, et al. Efficacy of a monthly compared to 3-monthly depot GnRH analogue (goserelin) in the treatment of children with central precocious puberty. Horm Res 2007; 68:157-163. During 24 months of therapy, it was found that more children receiving the 3-month-10.8 mg formulation of goserelin needed an increase in dosage frequency than those receiving the 1-month-3.6 mg formulation.
17. Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab 2007; 92:1697-1704. This article clearly shows the effectiveness of using a GnRHa delivered through a subcutaneous implant in suppressing both LH and sex steroids.
18. Klein KO. Affecting height outcomes in children with precocious puberty. Pediatr Endocrinol Rev 2007; 4 (Suppl 3):283-290. An excellent review of the various factors that have been shown to impact adult height.
19. Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab 2007; 92:3483-3489. This is the best study that has examined final height outcomes as a function of age of onset of puberty, and all of the girls in the three age groups were treated by the same protocol.
20. Klein KO, Barnes KM, Jones JV, et al. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001; 86:4711-4716.
21. Brito VN, Latronico AC, Cukier P, et al. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs. J Clin Endocrinol Metab 2008; 93:2662-2669. It was found that the interval between chronological age at onset of puberty and at the start of GnRHa therapy, height standard deviation scores at the start and end of therapy, and target height explained 74% of the adult height variance.
22. Vottero A, Pedori S, Verna M, et al. Final height in girls with central idiopathic precocious puberty treated with gonadotropin-releasing hormone analog and oxandrolone. J Clin Endocrinol Metab 2006; 91:1284-1287.